{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"54"}]}],"title":"Death events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"100"}]}],"title":"Censored events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Overall survival is reported here by the number of deaths from randomization until the data cut-off. Patients were censored at the time of database cut-off or the later of either the date of withdrawal or the date of last follow-up for patients who withdrew from study before the date of database cut-off. The survival time was analyzed using the Kaplan-Meier method.","groups":[{"description":"Participants began treatment with ruxolitinib 15 or 20 mg taken orally twice a day based on Baseline platelet count. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily.","id":"OG000","title":"Ruxolitinib"},{"description":"Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting pre-specified requirements were given the opportunity to cross over to ruxolitinib treatment.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"Week 144","title":"Overall Survival at Week 144","type":"SECONDARY","unitOfMeasure":"participants"}